MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 887 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
NMDAR/TRPM4-IN-2
CAS:<p>Potent NMDAR/TRPM4-IN-2 blocks NMDAR/TRPM4, protects brain and retinal neurons, and prevents mitochondrial dysfunction with an IC50 of 2.1 μM.</p>Fórmula:C11H19BrCl2N2Pureza:98.77%Cor e Forma:SolidPeso molecular:330.092EO-1606
CAS:<p>EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.</p>Fórmula:C21H17ClFNOPureza:98.28% - 98.84%Cor e Forma:SolidPeso molecular:353.82JNK-IN-11
CAS:<p>JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.</p>Fórmula:C12H11NO3S2Pureza:98.82%Cor e Forma:SolidPeso molecular:281.35DS12881479
CAS:<p>DS12881479 can be used in cancer research which is a potent and selective inhibitor of Mnk1(IC 50 =21 nM) [1].</p>Fórmula:C16H19N3OSPureza:99.85%Cor e Forma:SolidPeso molecular:301.41L 731734
CAS:<p>L 731734 is a farnesyltransferase inhibitor.</p>Fórmula:C19H38N4O3SCor e Forma:SolidPeso molecular:402.6RAF mutant-IN-1
CAS:<p>RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).</p>Fórmula:C23H18Cl3FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:567.85ERK Inhibitor II (Negative control)
CAS:<p>ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.</p>Fórmula:C18H12N6OCor e Forma:SolidPeso molecular:328.33Pan-RAF kinase inhibitor 1
CAS:<p>Potent Pan-RAF inhibitor 1 targets RAF/MAPK pathway, curbing RAS-mutated cancer cell growth. (Patent WO2021110141A1, compound 16B)</p>Fórmula:C26H24F3N3O4Cor e Forma:SolidPeso molecular:499.48AZD4747
CAS:<p>AZD4747 is an inhibitor of the mutant GTPase KRASG12C that hasial antitumor activity for the study of pancreatic and colorectal adenocarcinoma.</p>Fórmula:C24H22ClFN2O3Pureza:99.36%Cor e Forma:SolidPeso molecular:440.89p38-α MAPK-IN-1
CAS:<p>p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with IC50 of 2300 nM and 5500 nM in EFC displacement assay and HTRF assay,respectively.</p>Fórmula:C27H35N5O3Pureza:99.93%Cor e Forma:SolidPeso molecular:477.6KRAS G12C inhibitor 14
CAS:KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor with an IC 50 of 18 nM [1].Fórmula:C24H19ClF2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:484.88SOS1-IN-8
CAS:<p>SOS1-IN-8 is an inhibitor of SOS1 and acts on SOS1-G12D (IC50: 11.6 nM) and SOS1-G12V (IC50: 40.7 nM).</p>Fórmula:C24H26F3N3O4Cor e Forma:SolidPeso molecular:477.48AMG-548 hydrochloride (864249-60-5 free base)
<p>AMG-548 hydrochloride is an orally active and selective p38α inhibitor (Ki: 0.5 nM) and shows slightly selective over p38β (Ki: 36 nM) and >1000 fold selective</p>Fórmula:C29H28ClN5OPureza:98%Cor e Forma:SolidPeso molecular:498.02KRAS G12C inhibitor 21
CAS:<p>KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.</p>Fórmula:C34H30ClN3O4Cor e Forma:SolidPeso molecular:580.07KRAS G12C inhibitor 13
CAS:<p>KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .</p>Fórmula:C40H46F3N7O4Pureza:98%Cor e Forma:SolidPeso molecular:745.83RPR203494
CAS:<p>RPR203494 is a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.</p>Fórmula:C26H29FN6O4Cor e Forma:SolidPeso molecular:508.54HPK1-IN-37
CAS:<p>HPK1-IN-37 (compound A85), with an IC50 value of 3.7 nM, is a potent inhibitor of HPK1.</p>Fórmula:C27H35N7O4Cor e Forma:SolidPeso molecular:521.61PROTAC KRAS G12C degrader-3
CAS:<p>PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].</p>Fórmula:C63H75ClN14O6Pureza:98%Cor e Forma:SolidPeso molecular:1159.81ERK1/2 inhibitor 8
CAS:<p>ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).</p>Fórmula:C23H20ClN7O2SCor e Forma:SolidPeso molecular:493.97Ras inhibitor 134
CAS:<p>Ras inhibitor 134 can be used in studies about Ras.</p>Fórmula:C23H21ClFN5O3Cor e Forma:SoildPeso molecular:469.9KRAS G12C mutant protein inhibitor A-1
CAS:<p>KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.</p>Fórmula:C31H26ClF4N7O2Cor e Forma:SolidPeso molecular:640.03Deltasonamide 1
CAS:<p>Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.</p>Fórmula:C30H39ClN6O4S2Cor e Forma:SolidPeso molecular:647.25(aS)-PH-797804
CAS:<p>(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating inhibitory concentration (IC50) values of 26 nM for p38α and 102 nM for p38β. This compound exhibits anti-inflammatory activity [1] [2].</p>Fórmula:C22H19BrF2N2O3Cor e Forma:SolidPeso molecular:477.3KRAS G12C inhibitor 61
CAS:<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Fórmula:C31H33ClFN7O2Pureza:98%Cor e Forma:SolidPeso molecular:590.09Laxiflorin B
CAS:<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Fórmula:C20H24O5Pureza:98%Cor e Forma:SolidPeso molecular:344.4KRAS G12C inhibitor 51
CAS:<p>KRAS G12C inhibitor 51 is a KRAS G12C inhibitor.</p>Fórmula:C33H35FN6O3Cor e Forma:SolidPeso molecular:582.67KRAS inhibitor-14
CAS:<p>KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.</p>Fórmula:C20H15Cl3FN3O2SCor e Forma:SolidPeso molecular:486.77JNK3 inhibitor-3
CAS:<p>JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.</p>Fórmula:C26H25N7O2Pureza:98%Cor e Forma:SolidPeso molecular:467.52MEK-IN-6 hydrate
CAS:<p>MEK-IN-6 hydrate (compound 69), a MEK inhibitor, exhibits an IC50 value of 2 nM in A375 cells [1].</p>Fórmula:C18H22FN3O5SPureza:98%Cor e Forma:SolidPeso molecular:411.45MEK-IN-6
CAS:<p>MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making it</p>Fórmula:C18H20FN3O4SPureza:98%Cor e Forma:SolidPeso molecular:393.43KRas G12C inhibitor 1
CAS:<p>KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.</p>Fórmula:C31H38N6O3Pureza:98%Cor e Forma:SolidPeso molecular:542.67TNIK&MAP4K4-IN-1
CAS:<p>TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, exhibiting IC50 values of 1.29 nM and <10 nM, respectively, in human</p>Fórmula:C25H23FN4O3Cor e Forma:SolidPeso molecular:446.47KRAS G12C inhibitor 34
CAS:<p>KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.</p>Fórmula:C32H32ClN5O3Cor e Forma:SolidPeso molecular:570.08Uplarafenib
CAS:<p>Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.</p>Fórmula:C22H21F3N4O4SPureza:99.85%Cor e Forma:SolidPeso molecular:494.49ERK1/2 inhibitor 7
CAS:<p>ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).</p>Fórmula:C23H22FN7OSCor e Forma:SolidPeso molecular:463.53HPK1-IN-9
CAS:<p>HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)</p>Fórmula:C30H33N7O2Cor e Forma:SolidPeso molecular:523.63SOS1-IN-16
CAS:<p>SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 of</p>Fórmula:C30H31F3N4O3Pureza:98%Cor e Forma:SolidPeso molecular:552.59KRAS G12C inhibitor 5
CAS:<p>KRAS G12C inhibitor 5 is a KRas G12C inhibitor.</p>Fórmula:C32H37N7O2Pureza:98%Cor e Forma:SolidPeso molecular:551.68pan-KRAS-IN-4
CAS:<p>Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].</p>Fórmula:C36H34F2N6O3Pureza:98%Cor e Forma:SolidPeso molecular:636.69KRAS inhibitor-18
CAS:<p>KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.</p>Fórmula:C20H15ClF3N3O2SCor e Forma:SolidPeso molecular:453.87SOS1-IN-7
CAS:<p>SOS1-IN-7 (compound 18-p1) is a potent inhibitor of SOS1 and acts on SOS1-G12D (IC50: 20 nM) and SOS1-G12V (IC50: 67 nM).</p>Fórmula:C23H25F3N4O3Cor e Forma:SolidPeso molecular:462.46KRAS G12C inhibitor 25
CAS:<p>KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).</p>Fórmula:C32H41N7O2Cor e Forma:SolidPeso molecular:555.71HPK1-IN-10
CAS:<p>HPK1-IN-10 inhibits HPK1, a MAP4K kinase from progenitor cells, with potential in treating HPK1 diseases, detailed in patent WO2021213317A1.</p>Fórmula:C31H34N6O2Cor e Forma:SolidPeso molecular:522.64SOS1/KRAS-IN-1
CAS:<p>SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].</p>Fórmula:C24H26F3N5OPureza:98%Cor e Forma:SolidPeso molecular:457.49SOS1-IN-5
CAS:<p>SOS1-IN-5, a potent pyrimidine inhibitor, disrupts RAS-SOS1, blocking KRAS activation.</p>Fórmula:C26H31F3N4O5Cor e Forma:SolidPeso molecular:536.54HPK1-IN-33
CAS:<p>HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.</p>Fórmula:C18H16ClFN6Cor e Forma:SolidPeso molecular:370.81GNE 220 hydrochloride
CAS:<p>GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H27ClN8Cor e Forma:SolidPeso molecular:474.99KRAS G12C inhibitor 53
CAS:<p>KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.</p>Fórmula:C21H14ClF2N5O2Cor e Forma:SolidPeso molecular:441.82B-Raf IN 5
CAS:<p>B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.</p>Fórmula:C23H18ClF3N6O3S2Cor e Forma:SolidPeso molecular:583.01HPK1-IN-11
CAS:<p>HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.</p>Fórmula:C27H25N5O2Cor e Forma:SolidPeso molecular:451.52SKF-86002 dihydrochloride
CAS:<p>p38 MAP kinase inhibitor</p>Fórmula:C16H14Cl2FN3SPureza:98%Cor e Forma:SolidPeso molecular:370.27K-Ras G12C-IN-1
CAS:K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.Fórmula:C22H23Cl2N3O3Cor e Forma:SolidPeso molecular:448.34HPK1-IN-27
CAS:<p>HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.</p>Fórmula:C26H23F3N4O4Cor e Forma:SolidPeso molecular:512.48KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Fórmula:C29H30Cl3FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:635.94p38 Kinase inhibitor 4
CAS:<p>Compound 135, also known as p38 Kinase Inhibitor 4, is a potent inhibitor of p38 [1].</p>Fórmula:C12H9Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:282.13ZG1077
CAS:<p>ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.</p>Fórmula:C33H33F2N5O5SCor e Forma:SolidPeso molecular:649.71FGTI-2734 mesylate (1247018-19-4 free base)
CAS:<p>FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.</p>Fórmula:C27H35FN6O5S2Pureza:98%Cor e Forma:SolidPeso molecular:606.73pan-KRAS-IN-3
CAS:<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Fórmula:C33H32F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:587.63SB 203580 sulfone
CAS:<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Fórmula:C21H16FN3O2SCor e Forma:SolidPeso molecular:393.43AZ-TAK1
CAS:<p>"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."</p>Fórmula:C25H28FN7O2Cor e Forma:SolidPeso molecular:477.53AMG-548 dihydrochloride (864249-60-5 free base)
<p>AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.</p>Fórmula:C29H29Cl2N5OPureza:98%Cor e Forma:SolidPeso molecular:534.48HPK1-IN-35
CAS:<p>HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.</p>Fórmula:C30H32N8O3SCor e Forma:SolidPeso molecular:584.69Rac1-IN-3
CAS:<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Fórmula:C21H23N7O2Pureza:98%Cor e Forma:SolidPeso molecular:405.45BI-0474
CAS:<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Fórmula:C30H37N9O2SPureza:99.61%Cor e Forma:SolidPeso molecular:587.74ERK-IN-2 free base
CAS:<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Fórmula:C16H17N5O2Cor e Forma:SolidPeso molecular:311.34(R)-VX-11e
CAS:<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Fórmula:C24H20Cl2FN5O2Pureza:98.73%Cor e Forma:SolidPeso molecular:500.35KRAS inhibitor-12
CAS:<p>KRAS inhibitor-12 blocks KRAS G12C (IC50: 0.537 μM) and p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancer study.</p>Fórmula:C19H16Cl2FN5OSCor e Forma:SolidPeso molecular:452.33KRAS G12C inhibitor 59
CAS:<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Fórmula:C32H39F6N7O5Pureza:98%Cor e Forma:SolidPeso molecular:715.69HPK1-IN-12
CAS:<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Cor e Forma:SolidPeso molecular:445.49HPK1-IN-13
CAS:<p>HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Cor e Forma:SolidPeso molecular:445.49Inflachromene
CAS:<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Fórmula:C21H19N3O4Pureza:97.36% - 99.88%Cor e Forma:SolidPeso molecular:377.39MNK inhibitor 9
CAS:<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Fórmula:C25H29N9OCor e Forma:SolidPeso molecular:471.56B-Raf IN 15
CAS:<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Fórmula:C19H15N3OSPureza:98%Cor e Forma:SolidPeso molecular:333.41KRAS inhibitor-11
<p>KRAS inhibitor-11 is a KRAS inhibitor .</p>Fórmula:C29H47N9O6Cor e Forma:SolidPeso molecular:617.74Glecirasib
CAS:<p>Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signaling</p>Fórmula:C31H26ClF4N7O2Pureza:99.7% - >99.99%Cor e Forma:SolidPeso molecular:640.03SOS1-IN-13
CAS:<p>SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.</p>Fórmula:C21H22F3N3O2Cor e Forma:SolidPeso molecular:405.41KRAS G12C inhibitor 1R
CAS:<p>KRAS G12C inhibitor 1R can be used in studies about Ras.</p>Fórmula:C31H36ClFN6O2Cor e Forma:SoildPeso molecular:579.11Raf inhibitor 3
CAS:<p>Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].</p>Fórmula:C18H19FN8O2SPureza:98%Cor e Forma:SolidPeso molecular:430.46KRAS G12C inhibitor 49
CAS:<p>KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.</p>Fórmula:C31H31ClN6O3Cor e Forma:SolidPeso molecular:571.07KRAS G12C inhibitor 35
CAS:<p>KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).</p>Fórmula:C31H27ClF2N6O3Cor e Forma:SolidPeso molecular:605.03GSK1790627
CAS:<p>GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].</p>Fórmula:C24H21FIN5O3Cor e Forma:SolidPeso molecular:573.36KRAS G12C inhibitor 30
CAS:<p>KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Fórmula:C25H22ClFN6O3Cor e Forma:SolidPeso molecular:508.93CMP3a
CAS:<p>CMP3a, a NEK2 inhibitor, hinders GBM in mice and enhances radiotherapy by disrupting EZH2.</p>Fórmula:C28H27F3N6O2SCor e Forma:SolidPeso molecular:568.61Org OD 02-0
CAS:<p>10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate</p>Fórmula:C22H30O2Pureza:98%Cor e Forma:SolidPeso molecular:326.47Kras binder 12
CAS:<p>Kras binder 12 can be used in studies about Ras.</p>Fórmula:C29H47N9O6Cor e Forma:SoildPeso molecular:617.74KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Fórmula:C55H57Br2ClFIN8O7Cor e Forma:SolidPeso molecular:1283.25DL-threo dihydrosphingosine
CAS:<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Fórmula:C18H39NO2Cor e Forma:SolidPeso molecular:301.51ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Fórmula:C31H32ClN7O3Pureza:98%Cor e Forma:SolidPeso molecular:586.08FGTI-2734
CAS:<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Fórmula:C26H31FN6O2SPureza:99.69%Cor e Forma:SolidPeso molecular:510.63GNE 220
CAS:<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H26N8Pureza:98%Cor e Forma:SolidPeso molecular:438.53XRP44X
CAS:<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Fórmula:C21H21ClN4OPureza:99.67%Cor e Forma:SolidPeso molecular:380.87TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Fórmula:C30H38N6OPureza:98%Cor e Forma:SolidPeso molecular:498.66CXJ-2
CAS:<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Fórmula:C55H87N15O22Pureza:98%Cor e Forma:SolidPeso molecular:1310.37DT-061
CAS:<p>DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.</p>Fórmula:C25H23F3N2O5SPureza:98%Cor e Forma:SolidPeso molecular:520.52KRAS G12C inhibitor 16
CAS:<p>KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.</p>Fórmula:C24H21ClFN3O3Pureza:97.84%Cor e Forma:SolidPeso molecular:453.89GGTI-297
CAS:<p>GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).</p>Fórmula:C26H31N3O3SCor e Forma:SolidPeso molecular:465.61KRAS G12C inhibitor 58
CAS:<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Fórmula:C51H64ClF4N9O8SPureza:98%Cor e Forma:SolidPeso molecular:1074.62MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Fórmula:C52H69F3IN7O6SPureza:98%Cor e Forma:SolidPeso molecular:1104.11JNK3 inhibitor-1
CAS:<p>JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.</p>Fórmula:C21H17ClFN5O2SCor e Forma:SolidPeso molecular:457.91KRAS G12D modulator-1
CAS:<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Fórmula:C30H36FN5O4Pureza:98%Cor e Forma:SolidPeso molecular:549.64
